SARS-CoV-2

[Nature Medicine] Binding and neutralizing antibodies at 28 days after the second dose were measured in infected and noninfected vaccine recipients.

[Cell Discovery] The authors presented both single-cell TCR-seq and RNA-seq to analyze the dynamics of TCR repertoire and immune metabolic functions of blood T cells collected from recently discharged COVID-19 patients.

[Acta Physiologica] Given the ability of SARS-COV-2 to infect human pluripotent stem cell-derived pancreatic cells in vitro and the presence of SARS-CoV-2 in pancreatic samples from COVID-19 patients strongly hints that SARS-CoV-2 can invade the pancreas and directly cause pancreatic injury and diabetes.

[Nature Communications] Investigators obtained two cross-neutralizing antibodies that target Sarbecoviruses’ receptor-binding domain with sub-picomolar affinities and potently neutralize authentic SARS-CoV-2.

[Pfizer, Inc.] Pfizer, Inc. announced the start of the Phase II/III EPIC-PEP (Evaluation of Protease Inhibition for COVID-19 in Post-Exposure Prophylaxis) study to evaluate the investigational novel oral antiviral candidate PF-07321332, co-administered with a low dose of ritonavir, for the prevention of COVID-19 infection.

[Journal of Perinatology] Scientists compared neonatal immunity after vaccination against SARS-CoV-2 during pregnancy to that achieved after maternal infection.